Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Miller, AA [1 ]
Case, D [1 ]
Atkins, J [1 ]
Giguere, J [1 ]
机构：
[1] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7132
引用
收藏
页码：649S / 649S
页数：1
相关论文
共 50 条
  • [21] PHASE II STUDY OF BIWEEKLY IRINOTECAN PLUS BEVACIZUMAB IN HEAVILY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Cardona, Andres F.
    Arrieta, Oscar
    Cuello, Mauricio
    Corrales, Luis
    Vargas, Carlos
    Martin, Claudio
    Carranza, Hernan
    Otero, Jorge M.
    Katherine Rodriguez, July
    Mas, Luis
    Archila, Pilar
    Bramuglia, Guillermo
    Pastran, Zulay
    Curcio, Elizabeth
    Rojas, Leonardo
    Bernal, Laura
    Campos Parra, Alma D.
    Giannikopoulos, Petros
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S881 - S882
  • [22] A phase II study of carboplatin and weekly docetaxel in advanced non-small cell lung cancer
    Moore, T
    Patel, T
    Segal, M
    Thompson, J
    Zangmeister, J
    Larrimer, N
    Merriman, N
    Chidiac, T
    LUNG CANCER, 2005, 49 : S259 - S259
  • [23] Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
    Nakadate, Megumi
    Yamazaki, Koichi
    Konishi, Jun
    Kinoshita, Ichiro
    Sukoh, Noriaki
    Harada, Masao
    Akie, Kenji
    Ogura, Shigeaki
    Ishida, Takashi
    Munakata, Mitsuru
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    ANTICANCER RESEARCH, 2006, 26 (5B) : 3767 - 3772
  • [24] Carboplatin and vinorelbine in advanced non-small cell lung cancer: A phase I/II study
    Masters, G
    ONCOLOGIST, 2001, 6 : 12 - 15
  • [25] Vinorelbine and carboplatin in elderly patients with metastatic non-small cell lung cancer (NSCLC): A multicenter phase II study
    Deppermann, Karl-Matthias
    Ukena, Dieter
    von Pawel, Joachim
    Koschel, Gabriele
    Reck, Martin
    Serke, Monika
    Huber, Rudolf-Maria
    Eberhardt, Wilfried
    Niederle, Norbert
    ANNALS OF ONCOLOGY, 2004, 15 : 183 - 183
  • [26] A multicenter phase II study of induction chemotherapy with gemcitabine and carboplatin in locally advanced non-small cell lung cancer (NSCLC)
    Aerts, Joachim G.
    van Klaveren, Rob J.
    Surmont, Veerle
    Senan, Suresh
    Tan, Yoeke
    Vernhout, Rene
    van Wijhe, Gerda
    Verhoeven, Gert T.
    Hoogsteden, Henk C.
    van Meerbeeck, Jan P.
    ANNALS OF ONCOLOGY, 2004, 15 : 174 - 175
  • [27] Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC)
    William, W. N., Jr.
    Kies, M. S.
    Fossella, F. V.
    Gladish, G.
    Heymach, J. V.
    Glisson, B. S.
    Tse, W. H.
    Liu, D.
    Herbst, R. S.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Phase II study of combination of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
    Mitsuoka, Shigeki
    Kudoh, Shinzoh
    Kimura, Tatsuo
    Yoshimura, Naruo
    Hirata, Kazuto
    ANNALS OF ONCOLOGY, 2006, 17 : 227 - 227
  • [29] A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
    Soejima, Kenzo
    Naoki, Katsuhiko
    Ishioka, Kota
    Nakamura, Morio
    Nakatani, Michie
    Kawada, Ichiro
    Watanabe, Hideo
    Nakachi, Ichiro
    Yasuda, Hiroyuki
    Satomi, Ryosuke
    Nakayama, Sohei
    Yoda, Satoshi
    Ikemura, Sinnosuke
    Terai, Hideki
    Sato, Takashi
    Ohgino, Keiko
    Arai, Daisuke
    Tani, Tetsuo
    Kuroda, Aoi
    Nishino, Makoto
    Betsuyaku, Tomoko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 513 - 519
  • [30] Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer
    Jiang, Lian
    Wang, Dao-yuan
    Zhu, Zhi-hua
    Tang, Liang-fa
    Hou, Xin-heng
    Zhao, Hong-da
    Xie, Zheng
    Wang, Dan-feng
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 449 - 453
12345